The clinical benefit of suicide gene therapy of tumors has been marginal, mostly due to the low gene transfer efficiency in vivo. The death -inducing ligand, TRAIL, effectively kills many tumor cell types, while sparing most normal tissues. We hypothesized that TRAIL may enhance HSV thymidine kinase / ganciclovir ( TK / GCV ) gene therapy of tumor cells by augmenting both target and bystander cell kill. Human SH -EP neuroblastoma cells expressing TK as well as bystander cells were effectively killed by apoptosis, and their clonogenicity was ablated following GCV. Human TRAIL enhanced TK / GCV -induced cell death and decreased clonogenicity of TK -expressing cells and also of bystander cells. Cooperation between TRAIL and TK / GCV depended both on caspase activation and on mitochondrial apoptogenic function because both the broad -spectrum caspase inhibitor zVAD.fmk and overexpression of Bcl -2 decreased enhancement of cell kill by TRAIL. Facilitation of TRAIL signalling by up -regulation of TRAIL receptors did not contribute to enhancement because cell surface expression of the agonistic TRAIL receptors 1 and 2 was not increased by TK / GCV. In conclusion, the concerted activation of caspases and the mitochondrial amplification of caspase activation by TK / GCV may explain the cooperative effect of TK / GCV and TRAIL on the kill of neuroblastoma cells. Because combined treatment also augmented the bystander cell kill, the addition of TRAIL may increase the efficacy of TK / GCV gene therapy of neuroblastoma.
T hymidine kinase /ganciclovir ( TK /GCV ) gene therapy can elicit different modes of tumor cell death. In many tumor cell types, apoptosis is the prevalent response to GCV of both TK -bearing cells 2, 12, 18, 28, 51 and of bystander cells. 5, 12, 19 Nonapoptotic, e.g., necrotic, cell death was reported in some tumor cell types such as B16 melanoma after TK /GCV therapy. 45 Within a given tumor cell type, the tumor cell may proceed by default along the apoptotic pathway but may switch to a nonapoptotic pathway if apoptosis is blocked, e.g., by Bcl -2 overexpression. 34 Apoptosis can start from two different pathways -the death receptor pathway and the mitochondrial pathwaywith both pathways eventually converging to activate effector caspases. 1, 37, 44, 49 TK / GCV -induced apoptosis in SH -EP neuroblastoma cells is triggered by ligand -independent aggregation of CD95, which recruits the adaptor molecule FADD and caspase -8, forming a death -inducing signaling complex ( DISC ). 2 Caspase-8 thus becomes activated and in turn activates downstream effector caspases by proteolytic cleavage, leading to apoptosis. TK /GCV also affects the second mitochondrial pathway of apoptosis induction. 3 TK / GCV induces a permeability transition in mitochondria releasing cytochrome c from the mitochondrial intermembrane space into the cytosol, thus activating caspases and leading to DNA fragmentation. Mitochondrial apoptogenic function induced by TK /GCV is controlled by Bcl -2 because overexpression of Bcl -2 blocks these changes. Receptor and mitochondrial pathways are interconnected in TK /GCV -induced apoptosis, with mitochondria forming an amplification loop because mitochondrial apoptogenic function is induced upon caspase activation possibly triggered by receptor signaling. 3 Advanced -stage neuroblastoma carries a poor prognosis despite aggressive therapy, necessitating new therapeutic strategies (reviewed in Ref. [32 ] ). Suicide gene therapy may be a possible approach for neuroblastoma ( reviewed in Ref. [ 4 ] ). In addition to poor specificity, low gene transfer efficacy severely limits this approach. Thus, the so -called bystander effect, which is the killing of bystander cells not carrying the suicide gene, 12, 35 is important, and increasing this effect becomes crucial. We therefore investigated whether the death ligand TRAIL, increases the efficacy of TK / GCV gene therapy of neuroblastoma cells by increasing kill not only of target cells but also of bystander cells. TRAIL is known to induce apoptosis by binding to its agonistic receptors, TRAIL -R1 and TRAIL-R2 ( KILLER, TRICK2). 49 Upon receptor aggregation, a DISC is formed, consisting of TRAIL, TRAIL -R1 and /or TRAIL-R2, FADD, and caspase-8. 26, 49 Following caspase -8 cleavage, the caspase cascade is activated. Whereas in some cell types mitochondrial apoptogenic function is dispensible for TRAIL -induced apoptosis, 47 mitochondria appear to contribute to TRAIL -mediated apoptosis in other cell types. 20 We found that TRAIL cooperates with TK / GCV in killing of both target and bystander neuroblastoma cells, depending on the concerted activation of caspases and on mitochondrial apoptogenic function. Thus, adding TRAIL to TK /GCV gene therapy may be a promising approach to the therapy of neuroblastoma.
Materials and methods

Drugs
GCV (Hoffmann -La Roche, Grenzach, Germany ), was provided as pure substance, dissolved in water, and stored at À 808C. Lyophilized recombinant human (rh) TRAIL ( PeproTech, Rocky Hill, NJ ) was dissolved in water and stored at À 808C. , 100 U /mL penicillin (Life Technologies ), 100 g /mL streptomycin ( Life Technologies ), 2 mM L -glutamine (Biochrom ), 0.5 mg /mL G418 (Life Technologies), or 0.5 mg /mL hygromycin ( Life Technologies ), as previously described. 2, 14, 44 Clonogenicity assay
Cells
2Â10
4 TK + or TK À cells per well were plated into 12-well plates, allowed to attach overnight, and then treated with GCV in indicated concentrations for 4 days. Cells still adherent were trypsinized and pooled with the cells already detached. Aliquots of this pools were replated into six -well plates at clonal density to assess clonogenicity. Colonies were visualized by crystal violet staining after 1 week.
Apoptosis assay
Quantification of DNA fragmentation was performed by FACS analysis of propidium iodide-stained nuclei as described. 38 Cells were analyzed for DNA content by flow cytometry (FACScan; Becton Dickinson, Heidelberg, Germany ) using CELLQuest software. The percentage of specific apoptosis was calculated as follows: [ experimental apoptosis (% )À spontaneous apoptosis in medium (% )]/ [ 100% À spontaneous apoptosis in medium ( %) ]Â100.
MTT assay
The tetrazolium dye procedure was performed as described, 10 with some modifications. Cells were incubated in RPMI 1640 without phenol red and without serum with 1 mg /mL MTT for 3 hours at 378C. The incubation medium was removed and formazan was dissolved with isopropanol. Optical density was measured with a Bio -Tek ELX800 photometer at 550 nm with the reference wave length set at 630 nm using wells without cells as blanks.
Measurement of TK / GCV -mediated sensitization to TRAIL and inhibition by zVAD.fmk 2Â10 4 cells/ well in six -well plates were treated with 10 M GCV for 24 hours, washed with PBS, and incubated for 48 hours with 10 ng /mL rhTRAIL. The broad -spectrum tripeptide inhibitor of caspases, benzyloxycarbonyl -ValAla-Asp -fluoromethylketone ( Z-VAD.fmk; Enzyme Systems Products, Livermore, CA ), was used at a concentration of 50 M for the initial 30 hours of the experiment followed by an additional dose of 30 M thereafter.
Western blot analysis
Cells were lysed for 30 minutes at 48C in PBS with 0.5% Triton X -100 (Serva, Heidelberg, Germany ) and 1 mM PMSF (Sigma, St. Louis, MO ) followed by high -speed centrifugation. Protein concentration was assayed using bicinchoninic acid (Pierce, Rockford, IL ). Forty micrograms of protein per lane was separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose ( Amersham Pharmacia, Braunschweig, Germany ). After blocking for 1 hour in PBS supplemented with 2% BSA ( Sigma ) and 0.1% Tween 20 ( Sigma), immunodetection of TRAIL, TRAIL -R1, TRAIL -R2, and -tubulin was done using mouse anti -TRAIL monoclonal antibody (1:1000; Pharmingen, Heidelberg, Germany ), rabbit anti -TRAIL -R1 polyclonal antibody ( 1:1000; Pharmingen ), goat anti -TRAIL -R2 polyclonal antibody ( 1:1000; R&D Systems, Wiesbaden, Germany ), or mouse anti--tubulin monoclonal antibody ( 1:5000; Sigma ), respectively, followed by goat antimouse IgG, goat antirabbit IgG, or goat antigoat IgG (1:5000; Santa Cruz Biotechnology, Heidelberg, Germany ). Enhanced chemiluminescence ( ECL; Amersham Pharmacia ) was used for detection.
Detection of TRAIL -R1 and TRAIL -R2 by flow cytometry
The surface expression of TRAIL -R1 and TRAIL -R2 was analyzed by flow cytometry using a FACScalibur and CELLQuest software (Becton Dickinson ). 5Â10
5 TK + and TK À cells were detached by 0.05% EDTA /PBS, washed in PBS, and then incubated with flow cytometry buffer (10% rabbit serum, 1% FCS, 0.01% sodium azide, in PBS ) for 30 minutes at 48C. After centrifugation, cells were incubated in flow cytometry buffer with 10 g/ mL mouse monoclonal antibodies against TRAIL-R1 and TRAIL -R2 ( HW101 and HW201, respectively; Nanotools, Heidelberg, Germany ) or mouse IgG 1 isotype control ( DAKO, Hamburg, Germany ) for 1 hour at 48C. Following two washes in flow cytometry, buffer cells were incubated with 5 g/mL biotinylated F( ab 0 ) 2 fragments of rabbit antimouse IgG ( DAKO ) for 20 minutes at 48C. Cells were washed two times in flow cytometry buffer and incubated with 1:20 streptavidin -phycoerythrin ( Sigma ) for 20 minutes
Cancer Gene Therapy TRAIL enhances TK/GCV gene therapy of neuroblastoma C Beltinger et al at 48C. After two washes, cells were resuspended in 1% paraformaldehyde and analyzed. A gate was set on living cells as determined by forward -side scatter and 10 4 cells were counted when possible. The ratio of mean fluorescence of specific antibody versus isotype control was determined and expressed as SFI. 
Blockage of TRAIL interaction with its receptors
Assessment of the bystander effect by clonogenicity assay
The first step of this assay was performed as described for the assessment of the bystander effect by the MTT assay. After incubation with GCV and TRAIL, cells still adherent were Figure 1 TK / GCV decreases proliferation and metabolic survival, increases apoptosis, and impairs clonogenicity in SH -EP neuroblastoma cells. 2Â10 4 TK + or TK À cells per well were seeded into 12 -well plates, allowed to attach overnight, and then treated with GCV in indicated concentrations for 4 days. Proliferation / metabolic survival, apoptosis, and clonogenicity were determined in parallel during the same experiments. Similar results were obtained in three independent experiments. A: TK / GCV reduces proliferation and metabolic survival in SH -EP neuroblastoma cells. Cells were treated with GCV for 4 days. Proliferation and metabolic survival was measured by the MTT assay. Results are means of sixplicates and are expressed as percentage of untreated controls. B: TK / GCV induces apoptosis in SH -EP neuroblastoma cells. Cells were treated for 4 days. Specific apoptosis was determined by FACS analysis of propidium iodide -stained DNA content, as described in Materials and methods. Percentage of specific apoptosis was calculated as follows: [ experimental apoptosis ( % ) À spontaneous apoptosis in medium ( % ) ] / [ 100% À spontaneous apoptosis in medium ( % ) ]Â100. Spontaneous apoptosis was less than 5%. Results are means of triplicates. C: TK / GCV ablates clonogenicity. Cells still adherent after GCV treatment were trypsinized and pooled with the cells already detached. Same volumes of these pools were replated into six -well plates at clonal density to assess clonogenicity. Colonies were visualized by crystal violet staining after 1 week of growth. The experiment was done in triplicates with similar results.
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Results
In previous work investigating the molecular mechanisms of TK /GCV -induced apoptosis, we noticed that TK /GCV sensitized to the death -inducing ligands CD95 ligand ( CD95L /FasL /APO -1 ) and TNF -. 2 Reasoning that TRAIL -a death -inducing ligand, which also interacts with members of the TNF receptor superfamily -may have similar effects but may be better suited for tumor therapy because of its preferential action on tumor cells, we investigated TK /GCV -induced sensitization to rhTRAIL in SH -EP neuroblastoma cells.
TK / GCV decreases proliferation and metabolic cell survival, increases apoptosis, and impairs clonogenicity of SH -EP neuroblastoma cells
Although apoptosis is a prevalent mode of cell death in TK / GCV therapy, 2, 3, 12 other death pathways, such as necrosis, are also operative in some tumor cell types. 45 In fact, TK / GCV -induced necrosis may be more effective than apoptosis in eliciting an immune response, 33 ,34 a major determinant of the bystander effect in vivo. In addition to inducing cell death, TK /GCV also decreases proliferation. 13 We therefore comprehensively assessed TK /GCV -induced effects in SH -EP neuroblastoma cells by complementary methods. TK /GCV decreased proliferation and metabolic cell survival, as measured by the MTT test ( Fig 1A ) . TK / GCV induced apoptosis, as determined by enumerating hypodiploid nuclei ( Fig 1B ) . Clonogenicity was ablated with TK / GCV at low doses of GCV ( Fig 1C ) . Unspecific toxicity, as shown by TK À cells, was minimal with the concentrations of GCV applied, which are within the plasma concentrations achievable in patients after intravenous infusion. 11, 27 These data show that TK /GCV is effective in SH -EP neuroblastoma cells by affecting proliferation, metabolic cell survival, apoptosis, and clonogenicity.
rhTRAIL cooperates with TK / GCV in killing SH -EP neuroblastoma cells depending on mutual activation of caspases
We first investigated whether SH -EP neuroblastoma cells were sensitive to rhTRAIL alone. As shown by Figure 2A , SH -EP cells were killed by rhTRAIL in a dose -dependent manner. Next we wanted to know whether rhTRAIL could enhance TK /GCV -induced cell death of SH -EP neuroblastoma. Whereas GCV and rhTRAIL given alone in low doses caused only limited apoptosis, TK /GCV and rhTRAIL given together cooperatively induced marked apoptosis in TK + cells, but not in TK À cells (Fig 2B ) . To determine potential mechanisms of this cooperative effect, we investigated whether cooperation could be decreased by blocking caspase activation, as has been described for conventional chemotherapy and TRAIL. 25 Indeed, the broad -spectrum caspase inhibitor, zVAD.fmk, decreased the cooperative effect of TK / GCV and rhTRAIL (Fig 2B ) . Both TK /GCV and rhTRAIL are known to trigger apoptosis through caspase activation. Because activation of caspases by one stimulus may sensitize to activation by the other stimulus, this suggests that mutual caspase activation constitutes one mechanism of cooperation.
rhTRAIL enhances TK / GCV -induced apoptosis of SH -EP neuroblastoma cells depending, in part, on mitochondrial apoptogenic function À cells per well in six -well plates were treated with 10 M GCV for 24 hours. Cells were washed with PBS, and fresh medium containing 10 ng / mL rhTRAIL was added for 48 hours. Caspase dependence was investigated by adding 50 M of the broadspectrum caspase inhibitor zVAD.fmk for 30 hours, followed by additional 30 M for the rest of the experiment. Apoptosis was determined by FACS analysis of propidium iodide -stained DNA content. Spontaneous apoptosis was less than 5%. Results are means of triplicates. Similar results were obtained in two independent experiments.
Mitochondrial amplification of death signals determines TK /GCV -induced apoptosis of SH -EP cells by release of
Cancer Gene Therapy TRAIL enhances TK/GCV gene therapy of neuroblastoma C Beltinger et al cytochrome c and activation of effector caspases, leading to DNA fragmentation. 3 We therefore wanted to know whether the cooperation between TK /GCV and rhTRAIL was influenced by mitochondrial apoptogenic function. To this end, we blocked mitochondrial apoptogenic function by overexpressing Bcl -2 in TK + cells. Cooperation between TK /GCV and TRAIL was markedly decreased in TK + / Bcl -2 + cells (Fig 2B ) , showing that cooperation depended in part on mitochondrial apoptogenic function. Because TK /GCV can trigger apoptosis through mitochondrial apoptogenic function, this suggests that TK /GCV -induced activation of mitochondrial apoptogenic function leading to caspase activation may sensitize SH -EP cell to rhTRAILinduced activation of caspases. This may constitute a second mechanism of cooperation between TK /GCV and rhTRAIL.
TK / GCV does not increase TRAIL -R1 and TRAIL -R2
TK /GCV could potentially sensitize to TRAIL by upregulation of the agonistic TRAIL receptors 1 and 2 in analogy to some conventional chemotherapeutic drugs 9, 15, 29, 36 or ionizing radiation. 8, 16 SH -EP cells express little TRAIL -R1, but abundant TRAIL -R2, on the cell surface ( data not shown ). However, cell surface expression of TRAIL-R1 and TRAIL -R2 was not induced following TK / GCV (data Cancer Gene Therapy TRAIL enhances TK/GCV gene therapy of neuroblastoma C Beltinger et al not shown ). Similarly, expression of neither receptor was induced on the mRNA and protein level as determined by Western blot and reverse transcription polymerase chain reaction ( data not shown ).
TK / GCV induces TRAIL, which, however, does not mediate cytotoxicity
Next we wanted to know whether endogenous TRAIL is induced by TK /GCV and, if so, whether it could contribute to TK / GCV -mediated apoptosis by acting in an autocrine fashion. Indeed, TRAIL protein was upregulated in TK + cells following TK / GCV ( Fig 3A ) . The kinetics of TRAIL up -regulation superimposed on the kinetics of TK /GCV -induced apoptosis ( data not shown ), suggesting an autocrine loop. However, the TRAILneutralizing TRAIL -R2 -Fc protein did not block TK / GCV -induced apoptosis, whereas it effectively blocked rhTRAIL -induced apoptosis (Fig 3B ) . These data exclude the interaction of up -regulated endogenous TRAIL with its cognate receptors as a cause of TK /GCV -induced apoptosis. As shown below, TRAIL -R2 -Fc also did not inhibit bystander killing of TK /GCV, showing that induced TRAIL also does not act in a paracrine mode on surrounding cells. However, these data do not exclude that up -regulated TRAIL reduces the amount of rhTRAIL needed to trigger apoptosis.
rhTRAIL adds to the bystander effect of TK / GCV in SH -EP neuroblastoma cells as measured by metabolic survival
Given the importance of the bystander effect in suicide gene therapy, we first investigated the extent of this effect in SH -EP neuroblastoma cells treated with TK /GCV. To this end, mixtures of TK + and TK À cells in increasing ratios were treated with GCV, and metabolic survival was measured by the MTT assay. We observed a clear bystander effect in SH -EP cells: 12.5% TK + cells added to TK À cells were sufficient to kill more than half of all tumor cells, whereas the addition of 50% TK + cells almost completely killed all tumor cells ( Fig 4A ) . Next we wanted to know whether administration of rhTRAIL would augment this bystander effect. Indeed, rhTRAIL added to the bystander effect specifically because the augmentation was inhibited by the TRAIL-neutralizing TRAIL-R2 -Fc protein ( Fig 4A ) . rhTRAIL adds to the bystander effect of TK / GCV in SH -EP neuroblastoma cells as measured by clonogenicity assay Clonogenicity may be a more relevant in vitro parameter for assessing efficacy of cancer therapy than determining metabolic survival. As shown in Figure 4B , a bystander effect was also apparent when clonogenicity was used as the readout: an addition of only 6.25% TK + cells sufficed to elicit a marked bystander effect. Importantly, rhTRAIL added to this bystander effect of TK / GCV. Similar results were obtained with higher percentages of TK + cells (data not shown). Although clonogenicity of bystander cells was not completely abolished, it was sufficiently decreased to suggest that the cooperative effect of TK /GCV and rhTRAIL may be of clinical relevance.
Discussion
Improvement of suicide gene therapy in the foreseeable future will likely come from combining this strategy with more proven complementary approaches, such as chemotherapy or biologicals. 46 Thus, we investigated whether the combination of TK /GCV with the death ligand TRAIL, increases the efficacy of TK /GCV gene therapy of neuroblastoma cells.
TK / GCV effectively decreased proliferation and metabolic survival, increased apoptosis, and impaired clonogenicity of human SH -EP neuroblastoma cells at GCV concentrations achievable in the patient. Interestingly, whereas low doses of GCV were sufficient to ablate clonogenicity, higher doses were necessary to reduce metabolic survival and to induce apoptosis.
TK / GCV and rhTRAIL were markedly synergistic in causing apoptosis of SH -EP cells. Cooperation between TK /GCV and rhTRAIL depended on caspase activation because the broad -spectrum caspase inhibitor, zVAD.fmk, ablated the cooperative effect. In SH -EP neuroblastoma cells, TK /GCV induces caspase activation and TK -induced apoptosis is caspase-dependent.
2 TRAIL -mediated apoptosis is also caspase -dependent. 31 Thus, concerted caspase activation by TK /GCV and rhTRAIL may reduce the dose of either stimulus needed to activate caspases because these are activated already to a certain degree by the other stimulus. We therefore propose that concerted caspase activation constitutes one mechanism of the cooperation between TK / GCV and rhTRAIL.
Cooperation between TK /GCV and rhTRAIL depended, in part, on the apoptogenic function of mitochondria because blockage by Bcl -2 decreased cooperation. TK / GCV treatment of SH -EP neuroblastoma cells has been shown to cause mitochondrial perturbations. 3 These included loss of the mitochondrial membrane potential, release of cytochrome c from mitochondria into the cytosol, and subsequent caspase activation and nuclear fragmentation. All these perturbations were inhibited by Bcl -2 overexpression. 3 Thus, TK /GCV -induced, mitochondrialmediated caspase activation may sensitize tumor cells for subsequent TRAIL -induced activation of caspases. Alternatively, TRAIL -induced caspase activation may facilitate TK /GCV -induced, mitochondria -amplified caspase activation. We therefore propose that induction of mitochondrial apoptogenic function by TK / GCV constitutes a second mechanism of cooperation between TK /GCV and TRAIL.
TK / GCV treatment induced endogenous TRAIL. Induced TRAIL did not mediate TK /GCV -triggered apoptosis in an autocrine fashion by binding to agonistic TRAIL receptors because neutralizing TRAIL by a TRAIL -R2 -Fc protein construct did not inhibit apoptosis. Similarly, no effect of TK /GCV -induced TRAIL was evident on bystander cells, excluding a TRAIL -mediated bystander effect, which has been described after TRAIL gene transfer into tumor cells. 24 Cancer Gene Therapy TRAIL enhances TK/GCV gene therapy of neuroblastoma C Beltinger et al However, induced TRAIL may be a minor contributor to the cooperation between TK / GCV and rhTRAIL by reducing the amount of exogenous TRAIL needed to reach a presumed threshold to trigger apoptosis. The most commonly described mechanism of sensitization to TRAIL by drugs and irradiation is up-regulation of TRAIL-R2 and, less commonly, TRAIL -R1. 8, 9, 16, 29, 36, 39 This mechanism is not operative in the cooperation between TRAIL and TK /GCV in the SH -EP cells studied because no up -regulation was observed following TK /GCV. TRAIL -R2 is a target gene of p53; 41, 52 thus, p53 mutations may abrogate up -regulation of TRAIL -R2 following TK /GCV. However, in SH -EP neuroblastoma cells, p53 is not mutated, 22 which is true for most neuroblastomas. Because the role of TRAIL -R3 and TRAIL -R4 in determining TRAIL sensitivity in nontransfected cells is controversial, we did not examine whether TK / GCV downregulates these decoy receptors. Potential mechanisms of sensitization by TK /GCV warranting further investigations include down -regulation of apoptosis inhibitors, such as FLIPs or IAP family members, and increased mitochondrial release of repressors of apoptosis inhibitors, such as Smac / DIABLO.
Cooperation between TK /GCV and TRAIL in TKbearing target cells only would be of limited clinical relevance because suicide gene therapy, and therefore any adjuvant to it, also has to kill bystander cells. TRAIL not only augmented target but also bystander cell kill. Assuming clonogenicity to be a more discriminative in vitro assay for the efficacy of antitumor agents compared to cell kill assays, it may be more important that TRAIL also decreased bystander clonogenicity. The mechanisms of the TK /GCV -mediated bystander effect include transfer of GCV triphosphate from the target cell to the bystander cell through gap junctions 6, 35 and uptake of apoptotic bodies from dying transfected cells by untransfected bystander cells. 12 TRAIL is constitutively expressed on murine natural killer ( NK ) cells in the liver and plays a substantial role in suppressing tumor metastasis. 42 Neuroblastoma metastasizes to the liver. Thus, TK /GCV -mediated sensitization to TRAIL may decrease established liver metastases of neuroblastoma by TRAIL -bearing liver NK cells.
Whereas the therapeutic index of TRAIL appears to be high, TRAIL may not be completely devoid of side effects on normal human cells and tissues such as astrocytes, 50 brain tissue, 40 hepatocytes, 23 and keratinocytes. 30 Thus, instead of adding TRAIL to TK -bearing tumor cells, one could transfer the TRAIL gene into the tumor cells -an approach shown to induce tumor cell apoptosis. 17, 24 Many poor-prognosis neuroblastomas are characterized by NMYC amplification. 7 A subset of NMYC -amplified neuroblastoma does not express caspase -8 because the CASP -8 gene is either deleted or silenced by methylation. 21, 43 Because caspase-8 is part of the DISC initiating TRAIL signaling, TK /GCV will not cooperate with rhTRAIL in these neuroblastoma cells. However, CASP -8 can be re -expressed in these cells either by gene transfer or by demethylating agents such as 5-Aza -2 0 -deoxycytidine, thus restoring sensitivity to TRAIL. 21, 43 Thus, assuming that our findings are not cell line -specific and can be confirmed in animal tumor models, combining TRAIL with TK / GCV gene therapy may be a potential approach to the therapy of neuroblastoma.
